1295OBlood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
2017
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
58
Citations
NaN
KQI